Time to reconsider the role of sentinel lymph node biopsy in melanoma.
Breslow thickness
hazard ration
immediate completion lymph node dissection
melanoma
multicenter selective lymphadenectomy trial
prognosis
sentinel lymph node biopsy
survival
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
17
09
2018
revised:
01
11
2018
accepted:
07
11
2018
pubmed:
25
11
2018
medline:
13
4
2019
entrez:
25
11
2018
Statut:
ppublish
Résumé
The Multicenter Selective Lymphadenectomy Trials indicate that there are no overall or melanoma-specific survival advantages to performing sentinel lymph node biopsy (SLNB) followed by immediate completion lymph node dissection compared with wide excision and observation for patients with positive sentinel nodes. These results make SLNB solely a staging procedure. The role of SLNB in the management of patients with melanoma deserves reappraisal. The potential marginal benefit of SLNB beyond the clinical and pathologic features of the melanoma has not been well studied. The use of sentinel lymph node status alone to accept and stratify patients into trials or to receive adjuvant treatment is not rational.
Identifiants
pubmed: 30471314
pii: S0190-9622(18)32952-9
doi: 10.1016/j.jaad.2018.11.026
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1168-1171Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2018 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.